Doximity, Inc. (DOCS)

Doximity stock has fallen during the software stock bust in 2026. The business is doing well, is highly profitable, and has a lock on the doctor social media market in the United States.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Doximity remains a Hold as growth visibility weakens and NRR declines to 112%, raising concerns over future expansion. Engagement and profitability are robust, with workflow tools reaching 720,000 unique prescribers and GAAP gross margin near 90%. DOCS boasts a strong balance sheet, $735 million in cash, no debt, and ongoing share repurchases, supporting downside protection.

Allianz Asset Management GmbH acquired a new stake in Doximity, Inc. (NASDAQ: DOCS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 78,250 shares of the company's stock, valued at approximately $5,724,000. Several other institutional investors have also added to or

William Blair sold 372,184 shares of Doximity; estimated trade size was $20.89 million (quarterly average pricing). Quarter-end Doximity position value fell by $184.77 million, reflecting both trading and price changes.

Pre-Market Stock Futures: Futures are trading lower after an incredible turnaround on Friday, with all major indices surging higher following a three-day massive sell-off that had pushed the stock market to the brink of a meltdown. The rally on Friday came in full force despite Amazon.com (NASDAQ: AMZN) being beaten down after posting earnings after... Here Are Monday's Top Wall Street Analyst Research Calls: Autozone, Doximity, Li Auto, Oracle, Robinhood Markets, Roblox, SoFi Technolgy, Terawulf and More.

Doximity, Inc. (NYSE: DOCS - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $33.32, but opened at $23.69. Doximity shares last traded at $25.50, with a volume of 4,525,362 shares. Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on DOCS

Netskope (NASDAQ: NTSK - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both mid-cap services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk. Valuation and Earnings This table compares Netskope and Doximity"s

DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.

Doximity's sales growth slowed to 10% in Q3, and its net income dipped. Worse yet, the company guided for sales growth of only 4% in the upcoming quarter.

Major stock indexes opened higher Friday, a day after equities sank amid risk-off sentiment. Still, the Nasdaq and S&P 500 were poised to register sharp weekly losses.

Costly plans push Amazon down, Bitcoin falls in crypto slump, and more

Doximity, Inc. (DOCS) Q3 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Doximity (DOCS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.45 per share a year ago.

Doximity, which operates an online networking service for medical professionals, reported third-quarter revenue of $185.05 million, beating estimates of $182.20 million, according to Benzinga Pro. Revenue was up 10% on a year-over-year basis.